Clinical TrialsThe company added Johns Hopkins Medicine as a clinical site to enroll patients into the ongoing 114-patient Phase 3 TIGeR-PaC study, showing confidence in study progress.
Market PotentialRenovoRx has a significant market potential with its focus on Locally Advanced Pancreatic Cancer, one of the deadliest cancers with very poor prognosis and outcomes.
ValuationRNXT, with a current valuation, is considered undervalued and could be attractive.